Mersana Therapeutics, a Cambridge-based clinical stage biopharmaceutical firm, is making strides in developing antibody drug conjugates (ADC) to treat cancer patients with unmet needs. The company's flagship products include the B7-H4-targeted Dolasynthen ADC candidate, XMT-1660, and the immunosynthen ADC, XMT-2056. Mersana Therapeutics has entered research and development collaborations with Janssen Biotech and Merck KGaA, while also collaborating with Asana BioSciences for the development of ADC product candidates. Founded in 2001 as Nanopharma Corp., the company changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. is committed to improving the lives of cancer patients through cutting-edge research and development of ADCs.